The vaccine exists. But access is rationed by price.
In a country where dengue claims hundreds of lives each year and strikes hardest in the margins, Brazil has gained a new tool against the disease — though access to it, for now, follows the familiar contours of inequality. Qdenga, a Japanese-made vaccine with broad efficacy across all four dengue strains, has arrived in private pharmacies at a price that places it beyond the reach of most Brazilians. The public health system weighs its options slowly, while the virus does not wait.
- Brazil recorded 920 dengue deaths through August 2023, with the elderly and chronically ill bearing the heaviest toll — and the mosquito season is not over.
- Qdenga's 80.2% efficacy and 90.4% reduction in hospitalizations represent a genuine clinical breakthrough, especially since it protects even those never previously exposed to the virus.
- At R$364–390 per dose — and two doses required — the vaccine is effectively a private-sector privilege in a country where dengue spreads most fiercely through underserved communities.
- The government body Conitec is evaluating SUS inclusion, but the process could stretch up to 270 days, leaving millions unprotected during a critical window.
- Brazil's own Butantan Institute is racing to complete trials of a domestically developed tetravalent vaccine by 2024, raising the possibility of a more equitable path to protection.
Brazil now has a licensed dengue vaccine on pharmacy shelves, but the question of who can actually use it hangs over its arrival. Qdenga, developed by Japan's Takeda Pharma and approved by Brazilian health authorities in March 2023, is available at private pharmacies for between R$364 and R$390 per dose — two doses required, three months apart. The price varies slightly by chain, but the barrier it represents is consistent.
The vaccine's clinical profile is notable. It works against all four dengue strains, covers people aged 4 to 60, and — unlike its predecessor Dengvaxia — protects individuals regardless of prior dengue exposure. Trials demonstrated 80.2% efficacy against infection and a 90.4% reduction in hospitalizations. Those numbers carry weight in a country that recorded 920 dengue deaths through August 2023, with more than half concentrated in the Southeast. São Paulo state alone lost 255 people, most of them elderly or living with chronic conditions.
Brazil's vaccination clinics association has welcomed Qdenga as meaningful progress. But the vaccine's scope is limited to dengue alone — it offers no protection against zika, chikungunya, or yellow fever, all of which travel by the same mosquito.
The Ministry of Health has expressed intent to bring Qdenga into the public SUS system, and the government commission Conitec is currently reviewing Takeda's inclusion request. The evaluation process, however, can take up to 270 days — time measured against a disease that does not observe bureaucratic calendars. Dengue is not selective about neighborhood or income; the virus finds standing water wherever it exists.
Meanwhile, the Butantan Institute in São Paulo is developing its own tetravalent vaccine, Butantan-DV, which showed 79.6% efficacy in trials and is expected to complete its research phase in 2024. Whether a homegrown solution might reach Brazilians more broadly — or more quickly — than an imported one remains an open and consequential question.
Brazil has a new weapon against dengue, but only those who can afford it will have access to it right now. Qdenga, a vaccine manufactured by Japan's Takeda Pharma, received regulatory approval from Brazil's health authority in March 2023 and is now being sold in private pharmacies and clinics across the country. The shot costs between 364 and 390 reais per dose, depending on which pharmacy chain you visit—Raia and Drogasil charge 364.32 reais, while São Paulo Drugstores and Pacheco ask 389.90 reais. Two doses are required, spaced three months apart.
What makes Qdenga significant is its breadth. The vaccine protects against all four dengue virus types and works for people aged 4 to 60, whether they have been exposed to the virus before or not. Clinical trials showed it prevents dengue infection with 80.2 percent effectiveness and reduces hospitalizations by as much as 90.4 percent. This last detail matters: dengue can kill, and it does. Through August 2023, Brazil recorded 920 deaths from the disease, with the Southeast region accounting for 515 of them. São Paulo state alone saw 255 deaths. The elderly and people with chronic conditions like diabetes and hypertension face the highest risk of severe complications.
The vaccine's arrival has been welcomed by Brazil's vaccination clinics association as an important step forward in fighting the disease. But there is a crucial limitation: Qdenga only protects against dengue. It offers no defense against other illnesses spread by the same mosquito—zika, yellow fever, chikungunya—that continue to circulate in Brazilian communities.
For now, Qdenga remains confined to the private healthcare system. The Ministry of Health has said it is working to make the vaccine accessible to all Brazilians through the public health system, known as the SUS. Since the vaccine's approval, a government commission called Conitec has been evaluating whether to add it to the public program. That evaluation can take up to 180 days, with the possibility of a 90-day extension. Takeda Pharma has already submitted a request for inclusion. There is no timeline for when—or if—the vaccine will be free.
This matters because dengue is not a disease of the wealthy. The virus spreads through standing water in poor neighborhoods as readily as anywhere else. While Brazil waits for a decision on public access, another option is being developed domestically. The Butantan Institute in São Paulo is working on its own four-strain dengue vaccine, called Butantan-DV, which showed 79.6 percent effectiveness in trials. That research is expected to be complete in 2024. Whether a homegrown vaccine will reach people faster or more equitably than an imported one remains an open question.
Citas Notables
The arrival of Qdenga to the Brazilian market represents an important advance in fighting the disease.— Brazilian Association of Vaccine Clinics (ABCVAC)
The Ministry of Health is working to make the new vaccine accessible to all Brazilians.— Brazil's Ministry of Health
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that Qdenga works for people who've never had dengue before, when the other vaccine available in Brazil doesn't?
Because dengue immunity is complicated. If you've had one type, you're protected against that type forever, but the other three types can still infect you—and a second infection is often worse. Dengvaxia only works for people who've already been infected at least once. Qdenga works for anyone, which means it can actually prevent first infections, not just second ones.
So why isn't this vaccine in the public system already?
Money, mostly. The government has to evaluate whether the cost is worth the benefit compared to other health priorities. That's what Conitec does. It's a real process, not bureaucratic foot-dragging, but it does mean wealthy people get protected first.
The source mentions that Butantan is developing its own vaccine. Is that a backup plan?
It's more than that. If Butantan-DV works and gets approved, Brazil wouldn't depend on Takeda's pricing or supply chains. A domestic vaccine could be cheaper to produce and easier to distribute through the SUS. But it won't be ready until next year at the earliest.
What about the people dying right now while all this is being decided?
That's the tension the story doesn't resolve. Nine hundred and twenty deaths through August, mostly in the Southeast, mostly among people who can't afford a private vaccine. The disease is still spreading. The vaccine exists. But access is rationed by price.
Does Qdenga protect against the other mosquito-borne diseases too?
No. That's an important limitation. The same mosquito carries zika, yellow fever, chikungunya. Qdenga only covers dengue. So even vaccinated people still need to protect themselves against the mosquito itself.